Diagnostic challenges in rapidly progressive dementia

References

• Geschwind MD, Haman A, Miller BL. Rapidly progressive dementia. Neurol Clin. 2007;25:783–807.
   PubMed Web of Science ®Google Scholar
• Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659–2668.
   PubMed Web of Science ®Google Scholar
• Soto ME, Andrieu S, Arbus C, et al. Rapid cognitive decline in Alzheimer’s disease. Consensus paper. J Nutr Health Aging. 2008;12(10):703–713.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Wolff M, Weitz M, et al. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124–1130.
   PubMedGoogle Scholar
• Gaig C, Valldeoriola F, Gelpi E, et al. Rapidly progressive diffuse Lewy body disease. Mov Disord. 2011;26(7):1316–1323.
   PubMed Web of Science ®Google Scholar
• Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Reviews Neurosci. 2010;11(3):155–159.
   PubMed Web of Science ®Google Scholar
• Poser S, Mollenhauer B, Kraubeta A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain. 1999;122(12):2345–2351.
   PubMedGoogle Scholar
• Geschwind MD, Shu H, Haman A, et al. Rapidly progressive dementia. Ann Neurol. 2008;64(1):97–108.
   PubMed Web of Science ®Google Scholar
• Chitravas N, Jung RS, Kofskey DM, et al. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol. 2011;70(3):437–444.
   PubMed Web of Science ®Google Scholar
• Grau-Rivera O, Gelpi E, Nos C, et al. Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series. Neurodegener Dis. 2015;15(6):350–360.
   PubMed Web of Science ®Google Scholar
• Geschwind MD. Rapidly progressive dementia. Continuum (Minneap Minn). 2016;22(2):510–537.
   PubMedGoogle Scholar
• Hermann P, Laux M, Glatzel M, et al. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology. 2018;91(4):e331–e338.
   PubMed Web of Science ®Google Scholar
• Stoeck K, Sanchez-Juan P, Gawinecka J, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain. 2012;135(10):3051–3061.
   PubMedGoogle Scholar
• Studart Neto A, Soares Neto HR, Simabukuro MM, et al. Rapidly progressive dementia: prevalence and causes in a neurologic unit of a tertiary hospital in Brazil. Alzheimer Dis Assoc Disord. 2017;31(3):239–243.
   PubMed Web of Science ®Google Scholar
• Anuja P, Venugopalan V, Darakhshan N, et al. Rapidly progressive dementia: an eight year (2008–2016) retrospective study. PLoS One. 2018 cited 2018 Jul 5;13. DOI:10.1371/journal.pone.0189832.
   Web of Science ®Google Scholar
• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–144.
   PubMed Web of Science ®Google Scholar
• Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64:1586–1591.
   PubMed Web of Science ®Google Scholar
• Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob-disease. Brain. 2006;129:2278–2287.
   PubMed Web of Science ®Google Scholar
• Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17:175–178.
   PubMed Web of Science ®Google Scholar
• McGuire LI, Peden AH, Orru CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2012;72:278–285.
   PubMed Web of Science ®Google Scholar
• Cramm M, Schmitz M, Karch A, et al. Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease. Mol Neurobiol. 2016;53(3):1896–1904.
   PubMed Web of Science ®Google Scholar
• Bongianni M, Orrù C, Groveman BR, et al. Diagnosis of human prion disease using real-time quaking-induced conversion testing of olfactory mucosa and cerebrospinal fluid samples. JAMA Neurol. 2017;74(2):155–162.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Iwasaki Y, Yoshikura N, et al. An autopsy-verified case of steroid-responsive encephalopathy with convulsion and a false-positive result from the real-time quaking-induced conversion assay. Prion. 2017;11:284–292.
   PubMed Web of Science ®Google Scholar
• Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76:1711–1719.
   PubMed Web of Science ®Google Scholar
• Fragoso DC, Gonçalves Filho AL, Pacheco FT, et al. Imaging of Creutzfeldt-Jakob disease: imaging patterns and their differential diagnosis. Radiographics. 2017;37(1):234–257.
   PubMed Web of Science ®Google Scholar
• Gaudino S, Gangemi E, Colantonio R, et al. Neuroradiology of human prion diseases, diagnosis and differential diagnosis. Radiol Med. 2017;122(5):369–385.
   PubMed Web of Science ®Google Scholar
• Heath CA, Cooper SA, Murray K, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol. 2010;67:761–770.
   PubMed Web of Science ®Google Scholar
• WHO. Global Surveillance, diagnosis, and Therapy of Human Transmissible spongiform Encephalopathies: Report of WHO consultation, February 9–11, 1998. Geneva, Switzerland.
   Google Scholar
• Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017;88(2):119–125.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Redyk K, Meissner B, et al. Clinical features of rapidly progressive Alzheimer’s disease. Dement Geriatr Cogn Disord. 2010;29:371–378.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Ahlskog JE, Parisi JE, et al. Rapidly progressive neurodegenerative dementias. Arch Neurol. 2009;66:201–207.
   PubMedGoogle Scholar
• Schmidt C, Haïk S, Satoh K, et al. Rapidly progressive Alzheimer’s disease: a multicenter update. J Alzheimers Dis. 2012;30(4):751–756.
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Capellari S, Parchi P. Rapidly progressive Alzheimer’s disease: contributions to clinical-pathological definition and diagnosis. J Alzheimers Dis. 2018;63(3):887–897.
   PubMed Web of Science ®Google Scholar
• Hecht M, Krämer LM, von Arnim CAF, et al. Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol. 2018;135(5):681–694.
   PubMed Web of Science ®Google Scholar
• Cohen ML, Kim C, Haldiman T, et al. Rapidly progressive Alzheimer’s disease features distinct structures of amyloid-β. Brain. 2015;138(4):1009–1022.
   PubMedGoogle Scholar
• Qiang W, Yau WM, Lu JX, et al. Structural variation in amyloid-β fibrils from Alzheimer’s disease clinical subtypes. Nature. 2017;541(7636):217–221.
   PubMed Web of Science ®Google Scholar
• Drummond E, Nayak S, Faustin A, et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. Acta Neuropathol. 2017;133(6):933–954.
   PubMed Web of Science ®Google Scholar
• Ba M, Li X, Ng KP, et al. The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer’s disease from the Alzheimer’s disease neuroimaging initiative database. Alzheimers Dement. 2017;3(1):107–113.
   Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018 Apr;14(4):535–562.
   PubMed Web of Science ®Google Scholar
• Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer’s disease therapy and prevention strategies. Annu Rev Med. 2017;68:413–430.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease. NICE Technology Appraisal Guidance 217 (Review of NICE Technology Appraisal Guidance 111). National Institute for Clinical Excellence. 2011.
   Google Scholar
• Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203–212.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurol. 2017;89(1):88–100.
   PubMed Web of Science ®Google Scholar
• Tartaglia MC, Johnson DY, Thai JN, et al. Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease. Can J Neurol Sci. 2012;39:304–310.
   PubMed Web of Science ®Google Scholar
• Graff-Radford J, Aakre J, Savica R, et al. Duration and pathologic correlates of Lewy body disease. JAMA Neurol. 2017;74(3):310–315.
   PubMed Web of Science ®Google Scholar
• Garcia-Esparcia P, López-González I, Grau-Rivera O, et al. Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Front Neurol. 2017;8:89.
   PubMedGoogle Scholar
• Llorens F, Schmitz M, Varges D, et al. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol. 2016;263(11):2271–2277.
   PubMed Web of Science ®Google Scholar
• Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812–818.
   PubMed Web of Science ®Google Scholar
• Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74(2):163–172.
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD006504.
   PubMed Web of Science ®Google Scholar
• Mori E, Ikeda M, Kosaka K, et al. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72:41–52.
   PubMed Web of Science ®Google Scholar
• Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo controlled trial. Lancet Neurol. 2010;9:969–977.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164:1491–1498.
   PubMed Web of Science ®Google Scholar
• Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in Parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153–156.
   PubMed Web of Science ®Google Scholar
• McCann H, Stevens CH, Cartwright H, et al. α-Synucleinopathy phenotypes. Parkinsonism Relat Disord. 2014;20(Suppl 1):S62–7.
   PubMedGoogle Scholar
• Bjornsdottir A, Gudmundsson G, Blondal H, et al. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry. 2013;84(2):136–140.
   PubMed Web of Science ®Google Scholar
• Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–676.
   PubMed Web of Science ®Google Scholar
• Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy: a position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Mov Disord. 2014;29:857–867.
   PubMedGoogle Scholar
• Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy: a review of the MSA biomarker initiative. Neurobiol Dis. 2015;80:29–41.
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Kontaxis T, Bonakis A, et al. Rapidly progressive dementia: causes found in a Greek tertiary referral center in Athens. Alzheimer Dis Assoc Disord. 2009;23:337–346.
   PubMed Web of Science ®Google Scholar
• Taniguchi-Watanabe S, Arai T, Kametani F, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131(2):267–280.
   PubMed Web of Science ®Google Scholar
• Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140(12):3329–3345.
   PubMed Web of Science ®Google Scholar
• Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130:2616–2635.
   PubMed Web of Science ®Google Scholar
• Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327–340.
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–864.
   PubMed Web of Science ®Google Scholar
• Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–2204.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–629.
   PubMed Web of Science ®Google Scholar
• O’Brian JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–1706.
   PubMed Web of Science ®Google Scholar
• Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology. 1993;43:250–260.
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci. 2013;5:17.
   PubMed Web of Science ®Google Scholar
• Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification consensus study. Alzheimers Dement. 2018;14(3):280–292.
   PubMed Web of Science ®Google Scholar
• Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease - systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–352.
   PubMed Web of Science ®Google Scholar
• Hermann P, Romero C, Schmidt C, et al. CSF biomarkers and neuropsychological profiles in patients with cerebral small-vessel disease. PLoS One. 2014 [cited 2018 Jul 5];7. DOI:10.1371/journal.pone.0105000
   Google Scholar
• Skillbäck T, Delsing L, Synnergren J, et al. CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging. 2017;59:1–9.
   PubMed Web of Science ®Google Scholar
• Sjögren M, Blomberg M, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001;66(3):510–516.
   PubMed Web of Science ®Google Scholar
• Zerr I, Schmitz M, Karch A, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018;14(6):751–763.
   PubMed Web of Science ®Google Scholar
• Bjerke M, Zetterberg H, Edman A, et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis. 2011;27(3):665–676.
   PubMed Web of Science ®Google Scholar
• Wallin A, Kapaki E, Boban M, et al. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. BMC Neurol. 2017;17(1):102.
   PubMed Web of Science ®Google Scholar
• Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782–792.
   PubMed Web of Science ®Google Scholar
• Gao B, Lyu C, Lerner A, et al. Controversy of posterior reversible encephalopathy syndrome: What have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry. 2018;89(1):14–20.
   PubMed Web of Science ®Google Scholar
• Vilela P. Acute stroke differential diagnosis: stroke mimics. Eur J Radiol. 2017;96:133–144.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 2007;262:442–451.
   Google Scholar
• Salvarani C, Brown RD Jr, Christianson TJ, et al. Adult primary central nervous system vasculitis treatment and course: analysis of one hundred sixty-three patients. Arthritis Rheumatol. 2015;67(6):1637–1645.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Brown RD Jr, Hunder GG. Adult primary central nervous system vasculitis. Lancet. 2012;9843:767–777.
   Google Scholar
• Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine. 1988;67:20–39.
   PubMed Web of Science ®Google Scholar
• Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835–844.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Dalmau J. Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8(7):380–390.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840–851.
   PubMed Web of Science ®Google Scholar
• Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology. 2015;85:235–239.
   PubMed Web of Science ®Google Scholar
• Graus F, Escudero D, Oleaga L, et al. Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol. 2018 [cited 2018 Jul 5];6. DOI:10.1111/ene.13661
   Google Scholar
• Afshari M, Afshari ZS, Schuele SU. Pearls & oysters: hashimoto encephalopathy. Neurology. 2012;29;78(22):134–137.
   Web of Science ®Google Scholar
• Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–1098.
   PubMed Web of Science ®Google Scholar
• Prüss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010;75:1735–1739.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
   PubMed Web of Science ®Google Scholar
• Tüzün E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118:737–743.
   PubMed Web of Science ®Google Scholar
• Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655–1667.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165.
   PubMed Web of Science ®Google Scholar
• Alford K, Vera JH. Cognitive impairment in people living with HIV in the ART era: a review. Br Med Bull. 2018 cited 2018 Jul 5;14. DOI:10.1093/bmb/ldy019.
   Web of Science ®Google Scholar
• Compain C, Sacre K, Puéchal X, et al. Central nervous systeminvolvement in Whipple disease: clinical study of 18patients and long-term follow-up. Medicine. 2013;92(6):324–330.
   PubMed Web of Science ®Google Scholar
• Rosenbloom MH, Atri A. The evaluation of rapidly progressive dementia. Neurologist. 2011;17(2):67–74.
   PubMed Web of Science ®Google Scholar
• Appleby BS, Lyketsos CG. Rapidly progressive dementias and the treatment of human prion diseases. Expert Opin Pharmacother. 2011;12:1–12.
   PubMed Web of Science ®Google Scholar
• Mahajan S, Appleby BS. Comprehensive and methodical: diagnostic and management approaches to rapidly progressive dementia. Curr Treat Options Neurol. 2017;19(11):40.
   PubMed Web of Science ®Google Scholar
• Van der Meulen M, Dirven L, Habets EJJ, et al. Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. Lancet Oncol. 2018;19(8):e407–e418.
   PubMed Web of Science ®Google Scholar
• Chinnery PF. Mitochondrial disorders overview. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews® [Internet]. [Updated 2000 Jun 8; Updated 2014 Aug 14]. Seattle (WA): University of Washington, Seattle; 1993–2018.
   Google Scholar
• Zhang Y, Gao T, Tao QQ. Spectrum of noncerebrovascular rapidly progressive cognitive deterioration: a 2-year retrospective study. Clin Interv Aging. 2017;12:1655–1659.
   PubMed Web of Science ®Google Scholar